We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 269

Patent safe harbor applies to supplemental new drug applications
  • Foley & Lardner LLP
  • USA
  • May 21 2015

On May 13, 2015, the Federal Circuit confirmed in Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc. that the safe harbor provisions of 35 U


First look at false marking under the AIA
  • Foley & Lardner LLP
  • USA
  • May 14 2015

In Sukumar v. Nautilus, Inc., the Federal Circuit took its first look at the standing requirements to bring a false marking case under the American


Federal Circuit finds no direct infringement of Akamai patents
  • Foley & Lardner LLP
  • USA
  • May 19 2015

The Federal Circuit issued its remand decision in Akamai Technologies, Inc. v. Limelight Networks, Inc., this time affirming the district court


California Supreme Court scrutinizes reverse payment ANDA settlements
  • Foley & Lardner LLP
  • USA
  • May 12 2015

In In Re Cipro Cases I & II, the California Supreme Court laid out a four-part rule of reason analysis for evaluating ANDA settlements that involve a


Judge finds biosimilar patent procedures optional
  • Foley & Lardner LLP
  • USA
  • March 23 2015

Judge Seeborg of the U.S. District Court for the Northern District of California issued an order inAmgen, Inc. v. Sandoz, Inc., ruling that the


Apotex has standing despite Benicar patent disclaimer
  • Foley & Lardner LLP
  • USA
  • April 9 2015

In Apotex Inc. v. Daiichi Sankyo, Inc., the Federal Circuit held that Apotex has standing to seek a declaratory judgment that it does not infringe


Humira patent invalid for obviousness type double patenting
  • Foley & Lardner LLP
  • USA
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering


Federal Circuit finds hole in “this” priority claim
  • Foley & Lardner LLP
  • USA
  • January 29 2014

In Medtronic CoreValve, LLC v. Edwards Lifesciences Corp., the Federal Circuit affirmed the district court's finding that the patent at issue was


Amicus briefs on biosimilar patent litigation
  • Foley & Lardner LLP
  • USA
  • April 23 2015

Amgen has appealed the district court decision denying its motion for a preliminary injunction to keep Sandoz' biosimilar version of Neupogen off


Federal Circuit finds distribution of glucose meters exhausts method patent claims
  • Foley & Lardner LLP
  • USA
  • November 14 2013

In LifeScan Scotland, Ltd. V. Shasta Technologies, LLC, the Federal Circuit found that LifeScan's distribution of its One-Touch Ultra glucose meters